Core Viewpoint - The National Medical Products Administration has approved the innovative drug Anlotinib (also known as Migalizumab) for the treatment of moderate to severe active Crohn's disease and ulcerative colitis in adults, which is expected to benefit more patients in China and improve their quality of life [1][2]. Group 1: Drug Approval and Mechanism - Anlotinib is a monoclonal antibody drug developed using biotechnology, specifically designed to block key inflammatory cytokines (IL-23p19 subunit) in the gut, thereby regulating excessive immune responses [1]. - The drug has already been approved in multiple countries and regions, including the US, Europe, and Japan, indicating its international recognition and potential effectiveness [1]. Group 2: Disease Impact and Patient Demographics - Inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis, is a chronic and recurrent condition that has seen an increase in prevalence in China due to lifestyle changes, with Crohn's disease affecting approximately 3-4 cases per 100,000 people and ulcerative colitis affecting 17-18 cases per 100,000 people [1]. - The disease predominantly affects young adults, leading to symptoms such as abdominal pain, diarrhea, and weight loss, which significantly impact patients' quality of life and can result in increased healthcare costs, approximately three times higher than that of the general population [2]. Group 3: Clinical Efficacy - Clinical studies indicate that about one-third of patients treated with Anlotinib can observe early improvements in intestinal inflammation within three months, and nearly half can achieve clinical remission after one year of treatment, marking a promising new option for patients who have not responded well to traditional medications or other biologics [2].

Core Insights - Eli Lilly's drugs, Anjoulai and Anjoulai Li (generic name: Mirikizumab), have been approved by the National Medical Products Administration for the treatment of moderate to severe active Crohn's Disease (CD) and Ulcerative Colitis (UC) in adults [1][3] Group 1: Product Approval and Significance - The approval of Anjoulai and Anjoulai Li marks a significant step for Eli Lilly in the inflammatory bowel disease (IBD) treatment field in China, being the first innovative drug approved in this area [1][3] - Anjoulai and Anjoulai Li are IgG4 monoclonal antibodies specifically targeting the IL-23 p19 subunit, selectively inhibiting the IL-23 pathway to modulate immune inflammatory responses [1][3] Group 2: Clinical Data and Efficacy - For Crohn's Disease, the VIVID-1 global phase 3 clinical study showed that 45% of patients in the Anjoulai group achieved clinical response at week 12 and clinical remission at week 52, compared to 20% in the placebo group (p<0.0001) [3] - In the same study, 38% of patients in the Anjoulai group achieved endoscopic response at week 52, compared to 9% in the placebo group (p<0.0001) [3] - For Ulcerative Colitis, the LUCENT global phase 3 clinical study indicated that 64% of patients in the Anjoulai group achieved clinical response after 12 weeks, with 24% achieving clinical remission, significantly outperforming the placebo group [4] Group 3: Safety Profile - In the VIVID-1 study, the most common adverse events reported in the Anjoulai group included COVID-19 infection, anemia, joint pain, headache, and upper respiratory infections [5] - The incidence of serious adverse events in the Anjoulai group was 2.8% after 12 weeks, compared to 5.3% in the placebo group, and serious infection rates were 0.7% versus 0.6% [5] - The discontinuation rate due to adverse events was lower in the Anjoulai group compared to the placebo group during both the induction and maintenance phases [5]